It’s not easy to get depression-detecting AI through the FDA
For the past seven years, the California-based startup Kintsugi has been developing AI designed to detect signs of depression and anxiety from a person's speech. But after failing to secure FDA clearance in time, the company is shutting down and releasing most of its technology a...
The Verge AI
Source

Generated insight by OnAirToday AI
Developing AI for sensitive health conditions like depression faces significant regulatory hurdles, as demonstrated by Kintsugi's struggle to gain FDA approval. This failure highlights the complex pathway for bringing AI-driven mental health tools from research to accessible clinical application.
Get the day's AI news in one short email. Free.
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.